IDORSIA N (IDIA)

Sell: 3.865 CHF|Buy: 3.87 CHF|Change: 0.07 (-1.90%)

Open

3.97 CHF

Previous close

3.945 CHF

Trade high

4.06 CHF

Volume

1,095,353

Year high

4.85 CHF

Year low

0.6325 CHF

Dividend yield

–

Market capitalisation

950.93 mn CHF

P/E ratio

4.96

ISIN

CH0363463438

This share can be held in a Dealing account Stocks and shares ISA Lifetime ISA JISA SIPP

Share price

Performance 16/12/2025

1D | 1M | 3M | 1Y | 3Y ann | 5Y ann | 10Y ann

	Total return (%)
IDORSIA N	- 2.11
More...

Company profile

Idorsia Ltd is a biopharmaceutical company engaged in discovering, developing, and commercializing of medicines for unmet medical needs. It is a biotech hub of Europe specialized in the discovery and development of small molecules, to provide new therapeutic options. The company focuses on multiple therapeutic areas which include the central nervous system, cardiovascular disorders, immunological disorders, and orphan diseases. Idorsia's development compounds target a numberof different diseases such as Resistant Hypertension, lupus, insomnia, Cerebral vasospasm, and Fabry disease. Geographically, it derives revenue from Switzerland.

Sector

Healthcare

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.